APPENDIX 2: INCLUDED RECORDS

Note: The list of excluded studies is available from the corresponding author upon request.

1. Abbot Vascular. XIENCE V USA dual antiplatelet therapy (DAPT) cohort (XVU-AV DAPT). NCT01106534. 2016. Clinical trials.gov. https://clinicaltrials.gov/ct2/show/NCT01106534
2. Adamo M, Costa F, Vranckx P, et al. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. *Int J Cardiol*. 2015;190:242.
3. Beijing Anzhen Hospital. Twelve vs 24 months of dual antiplatelet therapy in patients with coronary revascularization for in-stent restenosis. NCT02402491. Clinical trials.gov. https://clinicaltrials.gov/ct2/show/NCT02402491
4. Campo G, Tebaldi M, Vranckx P, et al. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: A PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). *J Am Coll Cardiol*. 2014;63(6):506.
5. Collet JP, Cayla G, Cuisset T, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. *Am Heart J*. 2011;161(1):5.
6. Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): A randomised trial. *Lancet*. 2014;384:1577-1585.
7. Collet JP, Silvain J, Kerneis M, et al. Clinical outcome of first- vs second-generation DES according to DAPT duration: Results of ARCTIC-Generation. *Clin Cardiol*. 2016;39(4):192.
8. Cordis Corporation. CYPRESS-CYPHER for evaluating sustained safety. NCT00954707. 2016. Clinical trials.gov. https://clinicaltrials.gov/ct2/show/NCT00954707
9. Costa F, Adamo M, Ariotti S, et al. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. *EuroIntervention*. 2016;11(11):e1222.
10. Costa F, Vranckx P, Leonardi S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. *Eur Heart J*. 2015;36(20):1242.
11. Crimi G, Leonardi S, Costa F, et al. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. *Int J Cardiol*. 2016;212:110.
12. Crimi G, Leonardi S, Costa F, et al. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. Insights from the all-comer PRODIGY trial. *Catheter Cardiovasc Interv*. 2015;86(1):E19.
13. Dadjou Y, Safavi S, Kojuri J. Risks and benefits of dual antiplatelet therapy beyond 12 months after coronary stenting: A prospective randomized cohort study. *Medicine (Baltimore)*. 2016;95(22):e3663.
14. Didier R, Morice MC, Barragan P, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: Final results of the ITALIC

Appendix 2, as supplied by the authors. Appendix to: Elliott J, Kelly SE, Bai Z, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open* 2023. doi:10.9778/cmajo.2021-0119.

trial (Is There a Life for DES After Discontinuation of Clopidogrel). *JACC Cardiovasc Interv*. 2017;10(12):1202.
15. Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY randomized clinical trial. *JAMA Cardiol*. 2016;1(7):795.
16. Gargiulo G, Ariotti S, Santucci A, et al. Impact of sex on 2-year clinical outcomes in patients treated with 6-month or 24-month dual-antiplatelet therapy duration: A pre-specified analysis from the PRODIGY trial. *JACC Cardiovasc Interv*. 2016;9(17):1780.
17. Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. *Am Heart J*. 2016;174:95.
18. Gargiulo G, Santucci A, Piccolo R, et al. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. *Catheter Cardiovasc Interv*. 2017;90(4):E73-E84.
19. Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement. *Circulation*. 2015;131(1):62.
20. Gilard M, Barragan P, Noryani AAL, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial. *J Am Coll Cardiol*. 2015;65:777-786.
21. Helft G, Le Feuvew C, Georges JL, et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: The OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: Study protocol for a randomized controlled trial. *Trials*. 2013;14(56):1-6.
22. Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. *Eur Heart J*. 2016;37(4):365.
23. Hermiller JB, Krucoff MW, Kereiakes DJ, et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. *JACC Cardiovasc Interv*. 2016;9(2):138.
24. Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. *J Am Coll Cardiol*. 2016;67(21):2492.
25. Kereiakes DJ, Yeh RW, Massaro JM, et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: The dual antiplatelet therapy randomized clinical trial. *JAMA*. 2015;313(11):1113.
26. Kereiakes DJ, Yeh RW, Massaro JM, et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. *JACC Cardiovasc Interv*. 2015;8(12):1552.
27. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation a randomized, controlled trial. *Circulation*. 2014;129:304-312.
28. Lee JM, Cho DK, Hahn JY, et al. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. *Am Heart J*. 2016;182:1.
29. Lee, C.W. Short-term dual antiplatelet and maintenance clopidogrel therapy after drug eluting stent implantation (STAMP-DES). NCT02494284. Clinical trials.gov. https://clinicaltrials.gov/ct2/show/NCT02494284

Appendix 2, as supplied by the authors. Appendix to: Elliott J, Kelly SE, Bai Z, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open* 2023. doi:10.9778/cmajo.2021-0119.

30. Matteau A, Yeh RW, Kereiakes D, et al. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). *Am J Cardiol*. 2014;113(7):1146.
31. Mauri L, Elmariah S, Yeh RW, et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. *Eur Heart J*. 2016;37(4):378.
32. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. *Am Heart J*. 2010;160(6):1035.
33. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*. 2014;371(23):2155-66
34. Meredith IT, Tanguay JF, Kereiakes DJ, et al. Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized Dual Antiplatelet Therapy Study. *Circulation*. 2016;133(18):1772.
35. Nakamura M, Iijima R, Ako J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. *JACC Cardiovasc Interv*. 2017;10(12):1189.
36. Piccolo R, Gargiulo G, Franzone A, et al. Use of the Dual-Antiplatelet Therapy Score to guide treatment duration after percutaneous coronary intervention. *Ann Intern Med*. 2017;167(1):17.
37. Piccolo R, Magnani G, Ariotti S, et al. Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. *EuroIntervention*. 2017;13(1):78.
38. Resor CD, Nathan A, Kereiakes DJ, et al. Impact of optimal medical therapy in the Dual Antiplatelet Therapy Study. *Circulation*. 2016;134(14):989.
39. Schmidt ACS, Kereiakes DJ, Cutlip DE, et al. Myocardial infarction risk after discontinuation of thienopyridine therapy in the randomized DAPT Study (Dual Antiplatelet Therapy). *Circulation*. 2017;135(18):1720.
40. Secemsky EA, Yeh RW, Kereiakes DJ, et al. Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: A secondary analysis of the Dual Antiplatelet Therapy (DAPT) study. *JAMA Cardiol*. 2017;2:478-487.
41. Secemsky EA, Yeh RW, Kereiakes DJ, et al. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: A subanalysis of the dual antiplatelet therapy study. *JACC Cardiovasc Interv*. 2017;10:942-954.
42. Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). *Eur Heart J*. 2013;34(12):909.
43. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. *Circulation*. 2012 Apr 24;125(16):2015-26
44. Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). *Am Heart J*. 2010;160(5):804.

Appendix 2, as supplied by the authors. Appendix to: Elliott J, Kelly SE, Bai Z, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open* 2023. doi:10.9778/cmajo.2021-0119.

45. Valgimigli M, Tebaldi M, Borghesi M, et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: A pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). *JACC Cardiovasc Interv*. 2014;7(1):20.
46. Vranckx P, Leonardi S, Tebaldi M, et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. *Eur Heart J*. 2014;35(37):2524.
47. Yeh RW, Kereiakes DJ, Steg PG, et al. Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. *J Am Coll Cardiol*. 2017;70(18):2213.
48. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. *J Am Coll Cardiol*. 2015;65(20):2211.
49. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA.* 2016;315(16):1735.
50. Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial). https://clinicaltrialsgov/show/nct00781573. 2008.
51. P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold. https://clinicaltrialsgov/show/nct03119012. 2017.
52. Optimal antiplatelet therapy for high bleeding and ischemic risk patients trial (OPT-BIRISK). 2018. https://clinicaltrials.gov/ct2/show/NCT03431142
53. Berry NC, Kereiakes DJ, Yeh RW, et al. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. 2018;11(8):e005308.
54. Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;2018 Mar 09.
55. Kuroda K, Shinke T, Otake H, et al. Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial. *Heart and Vessels*. 2018;2018 Feb 20.
56. Berg D, Yeh RW, Mauri, L, et al. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J *Thrombosis Thrombolysis.* 2021;51:675.
57. Choi KH, Song YB, Lee JM, et al. Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An analysis from the SMART-DATE randomized trial. *Circulation: Cardiovascular Interventions.* 2020. 13: e008530.
58. Jang WJ, Lee JB, Song YB, et al. A randomized comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial. *EuroIntervention.* 2021;17:411-417.

Appendix 2, as supplied by the authors. Appendix to: Elliott J, Kelly SE, Bai Z, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open* 2023. doi:10.9778/cmajo.2021-0119.